Physician profile
John D Tran
NPI 1285677203
$1,916.27
in general payments reported to CMS, 2019-2025
18 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $57.89 · 2021: $55.91 · 2022: $657 · 2023: $469 · 2024: $153 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $316.49 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $309.55 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $214.94 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.54 | 2019-2023 | Jardiance |
| Pfizer INC. | $127.97 | 2019-2025 | |
| Novo Nordisk INC | $118.18 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $116.96 | 2022 | |
| Sanofi-Aventis U.S. LLC | $107.27 | 2019-2022 | |
| Amgen INC. | $104.03 | 2022 | |
| Novartis Pharmaceuticals Corporation | $95.96 | 2020-2024 | |
| Xeris Pharmaceuticals, INC. | $41.74 | 2022-2023 | Gvoke Hypopen |
| Nestle Healthcare Nutrition INC. | $39.16 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $35.26 | 2019-2022 | |
| Abbvie INC. | $30.97 | 2022 | |
| Exact Sciences Corporation | $30.05 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.31 | 2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $18.86 | 2025 | Gemtesa |
| Dexcom, INC. | $13.03 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.